Patents Assigned to Merz Pharma GmbH & Co. KGAA
  • Publication number: 20240238393
    Abstract: The present invention concerns a composition comprising (a) botulinum toxin and (b) non-crosslinked hyaluronic acid and its use of the treatment or prevention of dystonia, spasticity and/or wrinkles. Further, the present invention relates to a method for cosmetically smoothing or preventing wrinkles comprising the step of administering the present composition.
    Type: Application
    Filed: March 28, 2024
    Publication date: July 18, 2024
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Klaus FINK, Harold TAYLOR, Hermann RUSS, Peter BODERKE
  • Patent number: 11976110
    Abstract: The present invention pertains to a method for directly determining the biological activity of a Neurotoxin polypeptide in cells, comprising the steps of: a) incubating cells susceptible to Neurotoxin intoxication with a Neurotoxin polypeptide for a time and under conditions which allow for the Neurotoxin polypeptide to exert its biological activity; b) fixing the cells and, optionally, permeabilizing the cells with a detergent; c) contacting the cells with at least a first capture antibody specifically binding to the non-cleaved and Neurotoxin-cleaved substrate and with at least a second capture antibody specifically binding to the cleavage site of the Neurotoxin-cleaved substrate, under conditions which allow for binding of said capture antibodies to said substrates; d) contacting the cells with at least a first detection antibody specifically binding to the first capture antibody, under conditions which allow for binding of said first detection antibody to said first capture antibody, thus forming first de
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: May 7, 2024
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventor: Cornelia Brünn
  • Patent number: 11969461
    Abstract: The present invention concerns a composition comprising (a) botulinum toxin and (b) non-crosslinked hyaluronic acid and its use of the treatment or prevention of dystonia, spasticity and/or wrinkles. Further, the present invention relates to a method for cosmetically smoothing or preventing wrinkles comprising the step of administering the present composition.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 30, 2024
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Klaus Fink, Harold Taylor, Hermann Russ, Peter Boderke
  • Patent number: 11952601
    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: April 9, 2024
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
  • Patent number: 11819664
    Abstract: The present invention generally relates to a mixing nozzle (12) for mixing at least two liquid compositions such as a first liquid composition and a second liquid composition. The mixing nozzle (10) is configured to be coupled to a body (11) of a multi-component application device (10), in particular to a body (11) of a two-component syringe assembly, for injection of a liquid composition, which body (11) is configured to separately store said at least two solutions. The present invention further relates to a multi-component application device (10) comprising said mixing nozzle (12) and to a kit comprising said mixing nozzle (12) or said application device (10). Furthermore, the present invention relates to a method using said application device or said kit, for example for replacing or filling a biological tissue or increasing the volume of a biological tissue.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 21, 2023
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Franck Villain, Uwe Wortmann, Norbert Kaspers, Johannes Egger, Thomas Sowden Reinhold, Guido Popp, Michael Kunz, Jonathan Mason
  • Publication number: 20230277432
    Abstract: A liquid composition for improving the facial contour and shape of the human or animal face by injection, the liquid composition comprising water and at least one of the following components A, B and C: at least one component A, which leads to an osmotic concentration in the range from 500 to 5000 mOsm in the liquid composition, at least one high viscosity component B, which leads to a viscosity of the liquid composition in the range from 10 to 1500 mPas, at least one micro-particles component C, comprising micro-particles with an average particle size not larger than 0.25 mm, preferably in the range of 0.001 mm to 0.25 mm, and optionally comprising a local anesthetic compound D.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 7, 2023
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Sabine OTTO, Rainer POOTH, Benjamin HAGEDORN
  • Patent number: 11672750
    Abstract: The present invention relates to a dermal filler composition based on crosslinked hyaluronic acid, calcium phosphate material particles and carboxymethyl cellulose. The present invention further provides a process for preparing said dermal filler composition, and its use in cosmetic treatments such as for improvement of skin quality.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: June 13, 2023
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Roland Stragies, Nadine Hagedorn, Lubin Belkovi
  • Patent number: 11529398
    Abstract: This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: December 20, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Janos Csikos, Irena Pulte, Michael Althaus, Markus Krueer, Nico Wegener
  • Patent number: 11382960
    Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: July 12, 2022
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler
  • Patent number: 11357821
    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 14, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Juergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
  • Patent number: 11344573
    Abstract: The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: May 31, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Harry Frank Abst, Rainer Pooth, Martina Kerscher, Thomas Hengl, Birgit Blessmann-Gurk, Sabine Otto
  • Patent number: 11331434
    Abstract: The present invention relates a botulinum toxin prefilled syringe system with desirable injection force characteristics, in particular low gliding force and low break loose force, comprising a syringe barrel of glass containing a liquid botulinum toxin composition, a plunger stopper and a closure device such as a tip cap or a needle shield. In addition, the present invention relates to a kit comprising the botulinum toxin prefilled syringe system, and optionally instructions for use, and to the use of the botulinum toxin prefilled syringe system in therapeutic and cosmetic applications.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 17, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventor: Markus Vogt
  • Patent number: 11324672
    Abstract: The present invention generally relates to the field of hyaluronic acid (HA) dermal fillers, and more specifically to methods for preparing crosslinked HA-based compositions in the form of a gel comprising high-temperature dialysis and/or crosslinking in the presence of phosphate and an alkaline metal halide salt. The present invention further relates to crosslinked HA-based gel compositions prepared by said methods and their use as dermal fillers in aesthetic applications such as wrinkle treatments.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 10, 2022
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Nadine Hagedorn, Roland Stragies, Lubin Belkovi, Radia El-Banna
  • Publication number: 20220010294
    Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.
    Type: Application
    Filed: September 23, 2021
    Publication date: January 13, 2022
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
  • Patent number: 11219717
    Abstract: The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 11, 2022
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventor: Markus Vogt
  • Patent number: 11208501
    Abstract: The present invention relates to a process for depleting epoxide species in epoxy-crosslinked polysaccharide gel compositions. In addition, the present invention relates to crosslinked polysaccharide gel compositions made by said process and their use in cosmetic and therapeutic applications.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 28, 2021
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Ulrich Abel, Andreas Krause
  • Patent number: D973871
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: December 27, 2022
    Assignee: Merz Pharma GMBH & CO. KGAA
    Inventors: Dany Borowek, Kai Tiesberger, Sophie Costiou Charretour
  • Patent number: D973872
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: December 27, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Dany Borowek, Kai Tiesberger, Sophie Costiou Charretour
  • Patent number: D1013866
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: February 6, 2024
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Dany Borowek, Sophie Costiou Charretour, Kai Tiesberger
  • Patent number: D1013867
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: February 6, 2024
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Dany Borowek, Sophie Costiou Charretour, Kai Tiesberger